The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

The following is true of β-adrenergic blocker therapy
in CHF:
A. They are added to conventional therapy
after cardiac compensation is restored
B. They are indicated only in severe (NYHA
class IV) heart failure
C. They are to be used only at low doses
D. All of the above
by

1 Answer

Answer :

A. They are added to conventional therapy
after cardiac compensation is restored
by

Related questions

The following apply to use of spironolactone in CHF except: A. It is indicated only in NYHA class III/IV cases as additional drug to conventional therapy B. It affords prognostic benefit in severe heart failure over and above that afforded by ACE inhibitors C. It helps overcome refractoriness to diuretics D. It affords rapid symptomatic relief

Description : The following apply to use of spironolactone in CHF except: A. It is indicated only in NYHA class III/IV cases as additional drug to conventional therapy B. It affords prognostic benefit in ... by ACE inhibitors C. It helps overcome refractoriness to diuretics D. It affords rapid symptomatic relief

Last Answer : D. It affords rapid symptomatic relief

In patients of congestive heart failure, β-adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Description : In patients of congestive heart failure, β-adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Last Answer : D. Both B and C are correct

In patients of congestive heart failure, β -adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Description : In patients of congestive heart failure, β -adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Last Answer : D. Both B and C are correct

The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Description : The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Last Answer : B. They counteract deleterious effect of sympathetic overactivity on the myocardium

The basis for use of β -adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Description : The basis for use of β -adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Last Answer : B. They counteract deleterious effect of sympathetic overactivity on the myocardium

Angiotensin converting enzyme inhibitors afford maximum protection against progression of heart failure when used: A. At the higher therapeutic dose range over long term B. At the maximum tolerated dose only till haemodynamic compensation is restored C. At low doses over long term D. At low doses along with diuretics/digoxi

Description : Angiotensin converting enzyme inhibitors afford maximum protection against progression of heart failure when used: A. At the higher therapeutic dose range over long term B. At the maximum tolerated dose only till ... restored C. At low doses over long term D. At low doses along with diuretics/digoxi

Last Answer : A. At the higher therapeutic dose range over long term

Choose the correct statement about use of βadrenergic blockers in CHF: A. All β blockers are equally effective in CHF B. They are used as alternative to conventional therapy with ACE inhibitors ± digitalis/ diuretic C. They are most useful in mild to moderate cases with systolic dysfunction due to dilated cardiomyopathy D. They are indicated only in asymptomatic left ventricular dysfunction

Description : Choose the correct statement about use of βadrenergic blockers in CHF: A. All β blockers are equally effective in CHF B. They are used as alternative to conventional therapy with ... dysfunction due to dilated cardiomyopathy D. They are indicated only in asymptomatic left ventricular dysfunction

Last Answer : C. They are most useful in mild to moderate cases with systolic dysfunction due to dilated cardiomyopathy

The β3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Description : The β3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Last Answer : A. Is not blocked by the conventional doses of propranolol

The β 3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Description : The β 3 adrenoceptor differs from the other subtypes of β receptor in that it: A. Is not blocked by the conventional doses of propranolol B. Is located primarily in the heart C. Regulates blood sugar level D. Is not coupled to G proteins

Last Answer : A. Is not blocked by the conventional doses of propranolol

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

Digoxin affords the following benefit/benefits in CHF: A. Restores cardiac compensation and relieves symptoms B. Reverses the pathological changes of CHF C. Prolongs survival of CHF patients D. Both ‘A’ and ‘B’ are correc

Description : Digoxin affords the following benefit/benefits in CHF: A. Restores cardiac compensation and relieves symptoms B. Reverses the pathological changes of CHF C. Prolongs survival of CHF patients D. Both ‘A’ and ‘B’ are correc

Last Answer : A. Restores cardiac compensation and relieves symptoms

The preferred class of drugs for long term treatment of severe anxiety disorder with intermittent panic attacks is: A. Phenothiazine (chlorpromazine like) B. Azapirone (buspirone like) C. β-blocker (propranolol like) D. Selective serotonin reuptake inhibitor (sertraline like)

Description : The preferred class of drugs for long term treatment of severe anxiety disorder with intermittent panic attacks is: A. Phenothiazine (chlorpromazine like) B. Azapirone (buspirone like) C. β-blocker (propranolol like) D. Selective serotonin reuptake inhibitor (sertraline like)

Last Answer : DD. Selective serotonin reuptake inhibitor (sertraline like)

Beneficial effects of β-adrenoceptor blockers in CHF include the following except: A. Antagonism of ventricular wall stress enhancing action of sympathetic overactivity B. Antagonism of vasoconstriction due to sympathetic overactivity C. Prevention of pathological remodeling of ventricular myocardium D. Prevention of dangerous cardiac arrhythmias

Description : Beneficial effects of β-adrenoceptor blockers in CHF include the following except: A. Antagonism of ventricular wall stress enhancing action of sympathetic overactivity B. Antagonism ... Prevention of pathological remodeling of ventricular myocardium D. Prevention of dangerous cardiac arrhythmias

Last Answer : B. Antagonism of vasoconstriction due to sympathetic overactivity

β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β -adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

Milrinone is best used: A. In a patient of mild CHF B. As an additional drug alongwith conventional therapy to tide over crisis in refractory CHF C. For long-term maintenance therapy of CHF D. To suppress digitalis induced arrhythmias

Description : Milrinone is best used: A. In a patient of mild CHF B. As an additional drug alongwith conventional therapy to tide over crisis in refractory CHF C. For long-term maintenance therapy of CHF D. To suppress digitalis induced arrhythmias

Last Answer : B. As an additional drug alongwith conventional therapy to tide over crisis in refractory CHF

Because of proven beneficial effects on “cardiac remodeling”, these agents are now indicated as first line therapy in CHF patients. Which of the following is representative of this group of drugs? (a) Hydrochlorothiazide (b) Enalapril (c) Furosemide (d) Carvedilol (e) Bumetanide

Description : Because of proven beneficial effects on “cardiac remodeling”, these agents are now indicated as first line therapy in CHF patients. Which of the following is representative of this group of drugs? (a) Hydrochlorothiazide (b) Enalapril (c) Furosemide (d) Carvedilol (e) Bumetanide

Last Answer : Ans: B

Long-term maintenance therapy with digoxin is the best option in the following category of CHF patients: A. Hypertensive patients B. Patients with hypertrophic cardiomyopathy C. Patients with associated atrial fibrillation D. Patients having cardiac valvular defects

Description : Long-term maintenance therapy with digoxin is the best option in the following category of CHF patients: A. Hypertensive patients B. Patients with hypertrophic cardiomyopathy C. Patients with associated atrial fibrillation D. Patients having cardiac valvular defects

Last Answer : C. Patients with associated atrial fibrillation

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Description : Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Last Answer : D. Diuretics

Acute renal failure (ARF) may be caused by all of the following except (a) Acute tubular necrosis (ATN) due to drug therapy (e.g., aminoglycosides, contrast media) (b) Severe hypotension or circulatolry collapse (c) Decreased cardiac output, as from congestive heart failure (d) Hemolysis, myoglobinuria (e) Hyperkalemia

Description : Acute renal failure (ARF) may be caused by all of the following except (a) Acute tubular necrosis (ATN) due to drug therapy (e.g., aminoglycosides, contrast media) (b) Severe hypotension ... (c) Decreased cardiac output, as from congestive heart failure (d) Hemolysis, myoglobinuria (e) Hyperkalemia

Last Answer : Ans: E

The following type of vasodilator is not beneficial in CHF due to systolic dysfunction: A. Calcium channel blocker B. Angiotensin converting enzyme inhibitor C. Nitrate D. Hydralazine

Description : The following type of vasodilator is not beneficial in CHF due to systolic dysfunction: A. Calcium channel blocker B. Angiotensin converting enzyme inhibitor C. Nitrate D. Hydralazine

Last Answer : A. Calcium channel blocker

Glyceryl trinitrate is used in CHF for: A. Routine treatment of mild to moderate chronic heart failure B. Rapid symptom relief in acute left ventricular failure C. Arresting disease progression D. Both 'A' and 'B'

Description : Glyceryl trinitrate is used in CHF for: A. Routine treatment of mild to moderate chronic heart failure B. Rapid symptom relief in acute left ventricular failure C. Arresting disease progression D. Both 'A' and 'B'

Last Answer : D. Both 'A' and 'B

The dose of digoxin in congestive heart failure is adjusted by monitoring: A. Electrocardiogram B. Heart rate and symptoms of CHF C. Blood pressure D. Plasma digoxin levels

Description : The dose of digoxin in congestive heart failure is adjusted by monitoring: A. Electrocardiogram B. Heart rate and symptoms of CHF C. Blood pressure D. Plasma digoxin levels

Last Answer : B. Heart rate and symptoms of CH

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Along with effective antimicrobial therapy, corticosteroids are indicated in the following infective conditions except: A. Tubercular meningitis B. Severe P. carinii pneumonia in AIDS patient C. Herpes simplex keratitis D. Erythema nodosum leprosum

Description : Along with effective antimicrobial therapy, corticosteroids are indicated in the following infective conditions except: A. Tubercular meningitis B. Severe P. carinii pneumonia in AIDS patient C. Herpes simplex keratitis D. Erythema nodosum leprosum

Last Answer : C. Herpes simplex keratitis

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Which of the following is seen at low (analgesic) doses of aspirin: A. Respiratory stimulation B. Increased occult blood loss in stools C. Increased cardiac output D. Hyperglycaemia

Description :  Which of the following is seen at low (analgesic) doses of aspirin: A. Respiratory stimulation B. Increased occult blood loss in stools C. Increased cardiac output D. Hyperglycaemia

Last Answer : B. Increased occult blood loss in stools

A patient of chronic renal failure maintained on intermittent haemodialysis has anaemia not responding to iron therapy. Which of the following additional drug is indicated: A. Epoetin B. Cyanocobalamin C. Folic acid D. Pyridoxine

Description : A patient of chronic renal failure maintained on intermittent haemodialysis has anaemia not responding to iron therapy. Which of the following additional drug is indicated: A. Epoetin B. Cyanocobalamin C. Folic acid D. Pyridoxine

Last Answer : A. Epoetin

Raised plasma aldosterone level in CHF contributes to disease progression by exerting the following effects except: A. Fibrotic remodeling of myocardium B. Hyperkalemia and hypermagnesemia C. Increasing cardiac preload by Na+ and water retention D. Enhancing cardiotoxicity of sympathetic overactivity

Description : Raised plasma aldosterone level in CHF contributes to disease progression by exerting the following effects except: A. Fibrotic remodeling of myocardium B. Hyperkalemia and hypermagnesemia C. ... cardiac preload by Na+ and water retention D. Enhancing cardiotoxicity of sympathetic overactivity

Last Answer : B. Hyperkalemia and hypermagnesemia

Which vasodilator is most suitable for a patient of CHF who is symptomatic even at rest and has a central venous pressure of 25 mm Hg and cardiac index 1.8 L/min/m2 : A. Glyceryl trinitrate B. Enalapril C. Hydralazine D. Nifedipine

Description : Which vasodilator is most suitable for a patient of CHF who is symptomatic even at rest and has a central venous pressure of 25 mm Hg and cardiac index 1.8 L/min/m2 : A. Glyceryl trinitrate B. Enalapril C. Hydralazine D. Nifedipine

Last Answer : B. Enalapril

Select the drug that can help restore cardiac performance as well as prolong survival in CHF patients: A. Spironolactone B. Furosemide C. Dobutamine D. Metoprolol

Description : Select the drug that can help restore cardiac performance as well as prolong survival in CHF patients: A. Spironolactone B. Furosemide C. Dobutamine D. Metoprolol

Last Answer : D. Metoprolol

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Which of the following statement(s) is/are true concerning pharmacologic agents used in the treatment of shock? a. The primary difference between dopamine and dobutamine is the absence of significant a adrenergic activity b. The renal and mesenteric vasoconstrictive effects of norepinephrine complicate and sometimes restrict its use c. The apparent paradoxical use of vasodilators, such as nitroprusside, in shock is indicated as a means to augment cardiac function d. Isoproterenol with its potent b-adrenergic effect, is a particularly useful agent in the treatment of all forms of shock

Description : Which of the following statement(s) is/are true concerning pharmacologic agents used in the treatment of shock? a. The primary difference between dopamine and dobutamine is the absence of significant a ... b-adrenergic effect, is a particularly useful agent in the treatment of all forms of shock

Last Answer : Answer: a, b, c Therapeutic adjustments of intravascular volume (preload) and systemic vascular resistance (afterload) form the basis of the treatment strategies for all ... careful constant monitoring of arterial pressure and repeated hemodynamic measurements with a pulmonary artery catheter

A patient of CHF was treated with furosemide and digoxin. He became symptom-free and is stable for the last 3 months with resting heart rate 68/min in sinus rhythm but left ventricular ejection fraction is low. Which of the following lines of action is warranted: A. Stop above medication and start an ACE inhibitor B. Continue all medication as before C. Continue the diuretic but stop digoxin D. Continue digoxin but stop the diuretic

Description : A patient of CHF was treated with furosemide and digoxin. He became symptom-free and is stable for the last 3 months with resting heart rate 68/min in sinus rhythm but left ventricular ... medication as before C. Continue the diuretic but stop digoxin D. Continue digoxin but stop the diuretic

Last Answer : A. Stop above medication and start an ACE inhibitor

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The following calcium channel blocker is specifically indicated to counteract cerebral vasospasm and neurological sequelae following subarachnoid haemorrhage: A. Lacidipine B. Nimodipine C. Nicardipine D. Nitrendipine

Description : The following calcium channel blocker is specifically indicated to counteract cerebral vasospasm and neurological sequelae following subarachnoid haemorrhage: A. Lacidipine B. Nimodipine C. Nicardipine D. Nitrendipine

Last Answer : B. Nimodipine

The following is true of heparin except: A. Sudden stoppage of continuous heparin therapy causes rebound increase in blood coagulability B. High doses of heparin inhibit platelet aggregation C. Heparin is the physiologically active circulating anticoagulant D. Heparin clears lipemic plasma in vivo but not in vitro

Description : The following is true of heparin except: A. Sudden stoppage of continuous heparin therapy causes rebound increase in blood coagulability B. High doses of heparin inhibit platelet aggregation ... active circulating anticoagulant D. Heparin clears lipemic plasma in vivo but not in vitro

Last Answer : C. Heparin is the physiologically active circulating anticoagulant